BeOne Medicines AG cash flow to debt ratio of 56.38% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

BeOne Medicines AG's free cash flow has increased -240.61% from $-669.77M last year to $941.74M, signaling increasing performance

BeOne Medicines AG's debt to equity ratio is 0.43, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

BeOne Medicines AG's debt has increased relative to shareholder equity from 0.32 last year to 0.43 today, signaling weakened financials

BeOne Medicines AG has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

BeOne Medicines AG earns at least as much interest as it pays. Interest obligations are fully covered.

BeOne Medicines AG's profit margin has increased (-152.79%) in the last year from -16.92% to 8.93%, signaling increasing performance

BeOne Medicines AG's short-term assets of $6.23G exceed its short-term liabilities of $1.83G

BeOne Medicines AG's return on assets of 6.00% is higher than the 5.00% threshold, indicating efficient asset utilization

BeOne Medicines AG's return on equity of 12.10%, is lower than 15.00%, indicating bad performance

BeOne Medicines AG's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

BeOne Medicines AG had positive net income in only 1.00 out of 5 years, indicating unstable earnings

BeOne Medicines AG has positive free cash flow, indicating the company generates cash after capital expenditures

BeOne Medicines AG has a free cash flow yield of 2.87%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

BeOne Medicines AG's yearly earnings has increased -144.50% since last year from $-644.79M to $286.93M, signaling increasing performance

BeOne Medicines AG's yearly revenue has increased 40.23% since last year from $3.81G to $5.34G, signaling increasing performance

ROIC 7.74% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

BeOne Medicines AG's 3-year revenue CAGR of 55.69% is positive, indicating growing revenue over the past 3 years

BeOne Medicines AG had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

BeOne Medicines AG had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

BeOne Medicines AG has insufficient data to evaluate this check.

BeOne Medicines AG has an earnings yield of 0.12%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

BeOne Medicines AG is overvalued relative to its fair value price of 64.25 based on EBITDA multiple model

BeOne Medicines AG has an EV/EBITDA ratio of 48.98x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

BeOne Medicines AG is overvalued relative to its fair value price of -447.75 based on Earnings Fair Value model

BeOne Medicines AG has a PEG-ratio under 1 which is considered undervalued

BeOne Medicines AG has a price-to-book ratio of 91.99x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

BeOne Medicines AG has a price-to-sales ratio of 76.65x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue